Related Experiment Videos
Prevention and management of graft-versus-host disease. Practical recommendations
1Bone Marrow Transplant Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract:
Graft-versus-host disease (GVHD) is the leading cause of failure of allogeneic bone marrow transplantation. The disease typically involves the skin, liver and gastrointestinal tract, with death frequently resulting from infectious complications. Cyclosporin-based drug combinations are the mainstay of GVHD prophylaxis. The major toxicity of cyclosporin is renal dysfunction, and optimal strategies of therapeutic drug monitoring to minimise toxicity and maximise clinical efficacy have yet to be devised. Initial treatment of established GVHD usually includes high dose corticosteroids. Patients failing to respond to first line therapy have a poor prognosis. Investigational approaches to decreasing the mortality associated with GVHD include using monoclonal antibodies directed at specific T cell subsets, and T cell depletion of bone marrow grafts.
Insights
Graft-versus-host disease (GVHD) remains a major challenge in allogeneic bone marrow transplants, often leading to organ damage and infections. Research is exploring new strategies like monoclonal antibodies and T cell depletion to improve patient outcomes and reduce transplant failure.
Area of Science:
- Immunology
- Hematology
- Transplantation Medicine
Background:
- Graft-versus-host disease (GVHD) is a primary cause of allogeneic bone marrow transplant failure.
- GVHD commonly affects the skin, liver, and gastrointestinal tract, with infections posing a significant mortality risk.
- Cyclosporin-based prophylaxis is standard, but its renal toxicity necessitates optimized therapeutic drug monitoring.
Purpose of the Study:
- To review the current understanding of graft-versus-host disease (GVHD) in allogeneic bone marrow transplantation.
- To highlight the challenges in managing GVHD, including cyclosporin toxicity and treatment resistance.
- To discuss emerging investigational approaches for GVHD prophylaxis and treatment.
Main Methods:
- Literature review of graft-versus-host disease (GVHD) pathophysiology and management.
- Analysis of current prophylactic and therapeutic strategies for GVHD.
- Evaluation of novel treatment modalities, including monoclonal antibodies and T cell depletion.
Main Results:
- Graft-versus-host disease (GVHD) significantly impacts allogeneic bone marrow transplant success rates.
- Cyclosporin, a key prophylactic agent, presents considerable renal toxicity.
- High-dose corticosteroids are first-line treatment, but refractory cases have a poor prognosis.
Conclusions:
- Optimizing therapeutic drug monitoring for cyclosporin is crucial to balance efficacy and minimize renal toxicity.
- Investigational therapies, such as monoclonal antibodies targeting T cell subsets and T cell depletion of grafts, show promise in reducing GVHD-associated mortality.